Analyzing the recent Phase 2 Etrasimod data and comparing it to Celgene's ozanimod in ulcerative colitis patientsTicker(s): ARNA, CELG
A gastroenterologist who has significant experience treating UC patients and is familiar with the OASIS data.
Please describe your clinical practice and how many UC patients you treat.Added By: joe_mccann
How are you currently treating UC patients? Do you currently prescribe 5-aminosalicylic acid drugs such as sulfasalazine, mesalazine, or corticosteroids, and how well managed are your patients?
- Have you encountered severe adverse effects cases with the 5-ASA drugs, such as myelosuppression, pancreatitis, liver problems, myocarditis; as there have been reports of such risk when using Mesalazine.
Added By: joe_mccann
Adalimumab (Humira) has also been approved in the recent years for treatment in ulcerative colitis. What has been your experience with it? Having been approved for many other indications, has it seen broad use in your field?
What are your initial impressions of the P2 OASIS data released on 3/20? In the recent Phase 2 data release, the 1 mg group saw a 0.43 point improvement, and the 2 mg group, 0.99 in stool frequency, rectal bleeding and findings on endoscopy.
- Are those numbers relevant enough in your opinion to vouch for the drug's efficiency? How does it compare to the drugs in your first line of therapy
- Endoscopic improvement was also at 41.8% for the 2 mg group vs. 17.8% in the placebo group. What are your thoughts on this improvement?
Added By: joe_mccann
Does etrasimod have the potential to be used in stopping progression towards intraepithelial neoplasia or colitis-associated cancer, given those findings? Or are there better results to be found with other medications, in your opinion?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.